Nona Biosciences, a US-based global biotechnology company, announced on Friday that BeiGene Ltd, a US-based global, science-driven oncology company, has exercised its exclusive option to acquire global development, manufacturing and commercialisation rights for an antibody-drug conjugate (ADC) from DualityBio, a collaborator of Nona Biosciences.
This ADC was manufactured under the partnership contract set up between Nona Biosciences and DualityBio in 2022.
Under the terms of the agreement, Nona Biosciences granted DualityBio exclusive rights to certain monoclonal antibodies targeting specific tumours, enabling the development of first-in-class ADC candidates worldwide.
AstraZeneca's Imfinzi recommended for EU approval in resectable NSCLC treatment
Innovent Biologics doses first patient in registrational study assessing IBI363
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
AstraZeneca's camizestrant shows significant PFS benefit in HR+ breast cancer
FDA accepts Telix Pharmaceuticals' BLA for Zircaix and grants Priority Review
GSK announces USD1.15bn acquisition of IDRx
Summit Therapeutics and Pfizer partner to evaluate ivonescimab with ADCs in solid tumor trials
Bristol Myers Squibb's application for Opdivo-Yervoy combo in colorectal cancer accepted by U.S. FDA
Redx Pharma reports positive Phase 1 results for RXC008 in fibrostenotic Crohn's disease
Sectra and Siemens Healthineers collaborate to enhance radiology diagnostics
ValiRx Plc concludes evaluation project with Imperial College London
NKGen Biotech administers first dose of troculeucel to frontotemporal dementia patient